Weight-loss Drug Zepbound Eases Sleep Apnea in Company Trials

apnea "impacts 80 million adults in the U.S., with more than 20 million living with moderate-to-severe OSA. However, 85% of OSA cases go undiagnosed and therefore untreated," Dr. Jeff Emmick, senior vice president of product development at Lilly, said in a company news release announcing the results.

After 52 weeks, Zepbound prompted an average reduction of 27.4 events per hour in people who were not on PAP machines, compared to a reduction of 4.8 events per hour for people on a placebo.

Switzerland Neuesten Nachrichten, Switzerland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Herkunft: NBCNewsHealth - 🏆 707. / 51 Weiterlesen »